Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous tumor lysate-pulsed dendritic cell vaccine (Roswell Park)
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous tumor lysate-pulsed dendritic cell vaccine developed by Roswell Park Cancer Institute is an experimental cellular immunotherapy designed for patients with non-small cell lung cancer (NSCLC). The production process involves harvesting a patient's peripheral blood mononuclear cells to generate dendritic cells, which are then matured and "pulsed" with a lysate derived from the patient's own surgically resected tumor. This lysate contains a diverse array of autologous tumor-associated antigens. When administered intradermally, these antigen-presenting cells migrate to lymph nodes and activate cytotoxic T-lymphocytes, aiming to establish a systemic anti-tumor immune response to eliminate residual disease and prevent recurrence in patients with operable stage IB-IIIA NSCLC.
- Other names
- Autologous tumor lysate-pulsed dendritic cell vaccineAutologous tumor cell vaccineTherapeutic autologous dendritic cellsRPCI-NSCLC-DC
Beyond the preview
Go deeper on Autologous tumor lysate-pulsed dendritic cell vaccine (Roswell Park).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous tumor lysate-pulsed dendritic cell vaccine (Roswell Park).